Researchers identify genetic sensitivity to drug warfarin

The era of personalized medicine promised by the human genome project moved one step closer to reality today, with a University of Washington study that explains why some people are more sensitive than others to a common blood-thinning drug. The researchers found that gene variations determine whether people should get high, medium or low doses of the drug warfarin, also known by the brand name Coumadin. They also found that 90 percent of Asians carry low-dose versions of the genes, while African Americans are more likely to have high-dose versions. Dr. Francis Collins, director of the National Human Genome Research Institute, said the Seattle study is an example of the type of discoveries that should accelerate in coming years, building on the work of the ambitious effort to map the human genetic sequence completed two years ago."This is the kind of thing we have been hoping would start to happen, converting the dreams into reality," Collins said.

The Seattle Times: Health: UW researchers identify genetic sensitivity to drug

1 comment:

Pearlie Guerrier said...

Personalized medicine is one of the issues that is vital to health care. There are indeed differences on how a medicine would affect people of different races. This is necessary to be able to prescribe the best treatment.

Blog Archive